Intensified conditioning regimen with fludarabine combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in children with high-risk acute leukemia

References

• Shen S, Cai J, Chen J, et al. Long-term results of the risk-stratified treatment of childhood acute lymphoblastic leukemia in China. Hematol Oncol. 2018;36(4):679–688.
   PubMed Web of Science ®Google Scholar
• Ibrahimova A, Pommert L, Breese EH. Acute leukemia in infants. Curr Oncol Rep. 2021;23(3):27–36. doi:10.1007/s11912-021-01021-1
   PubMed Web of Science ®Google Scholar
• Takachi T, Watanabe T, Miyamura T, et al. Hematopoietic stem cell transplantation for infants with high-risk KMT2A gene rearranged acute lymphoblastic leukemia. Blood Adv. 2021;5(19):3891–3899.
   PubMed Web of Science ®Google Scholar
• Xu L, Chen H, Chen J, et al. Thrombospondin-2 promotes prostate cancer bone metastasis by the up-regulation of matrix metalloproteinase-2 through down-regulating miR-376c expression. J Hematol Oncol. 2017;10(1):33–49. doi:10.1186/s13045-017-0390-6
   PubMedGoogle Scholar
• Hyery K. Treatments for children and adolescents with AML. Blood Res. 2020;55(S1):S5–S13.
   PubMedGoogle Scholar
• Wang Y, Wu DP, Liu QF, et al. Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients. J Hematol Oncol. 2019;12(1):88–96. doi:10.1186/s13045-019-0781-y
   PubMed Web of Science ®Google Scholar
• Khan MA, Bashir Q, Chaudhry QU, et al. Review of haploidentical hematopoietic cell transplantation. J Glob Oncol. 2018;4:1–13.
   Web of Science ®Google Scholar
• Kato K, Nao Y, Kimikazu M, et al. Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia. Pediatr Blood Cancer. 2014;61(4):712–716. doi:10.1002/pbc.24922
   PubMed Web of Science ®Google Scholar
• Shargian-Alon L, Wolach O, Rozovski U, et al. Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia. Ann Hematol 2020;99(12):2939–2945. doi:10.1007/s00277-020-04232-x
   PubMed Web of Science ®Google Scholar
• Warrick K, Althouse SK, Rahrig A, et al. Factors associated with a prolonged hospital stay during induction chemotherapy in newly diagnosed high risk pediatric acute lymphoblastic leukemia. Leuk Res 2018;71:36–42. doi:10.1016/j.leukres.2018.06.013
   PubMed Web of Science ®Google Scholar
• Huschart E, Miller H, Salzberg D, et al. Azacitidine and prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation for pediatric high-risk acute myeloid leukemia. Pediatr Hematol Oncol. 2021;38(2):154–160.
   PubMed Web of Science ®Google Scholar
• Shargian-Alon L, Wolach O, Rozovski U, et al. Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia. Ann Hematol 2020;99(12):2939–2945.
   PubMed Web of Science ®Google Scholar
• Kazemi MH, Dehaghi BK, Roshandel E, et al. Oncolytic virotherapy in hematopoietic stem cell transplantation. Hum Immunol 2021;88(9):640–648.
   Google Scholar
• Shah RM. Contemporary haploidentical stem cell transplant strategies in children with hematological malignancies. Bone Marrow Transplant. 2021;56(7):1518–1534. doi:10.1038/s41409-021-01246-5
   PubMed Web of Science ®Google Scholar
• Yadav SP, Sharma A, Kapoor R, et al. Thiotepa based conditioning for haploidentical stem cell transplantation with post transplant cyclophosphamide for pediatric acute leukemia Is highly effective. Biol Blood Marr Transplant. 2020;26(3):S163–S164.
   Google Scholar
• Katsanis E, Sapp LN, Varner N, et al. Haploidentical bone marrow transplantation with post-transplant cyclophosphamide/bendamustine in pediatric and young adult patients with hematologic malignancies. Biol Blood Marrow Transplant. 2018;24(10):2034–2039. doi:10.1016/j.bbmt.2018.06.007
   PubMed Web of Science ®Google Scholar
• Uygun V, Karasu G, Dalolu H, et al. Haploidentical hematopoietic stem cell transplantation with post-transplant high-dose cyclophosphamide in high-risk children: a single-center study. Pediatr Transplant. 2019;23(7):e13546–e13555.
   PubMed Web of Science ®Google Scholar
• O’Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood and Marrow Transplant. 2002;8(7):377–386. doi:10.1053/bbmt.2002.v8.pm12171484
   PubMed Web of Science ®Google Scholar
• Ahmed S, Kanakry JA, Ahn KW, et al. Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide–based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for Hodgkin lymphoma. Biol Blood and Marrow Transplant. 2019;25(9):1859–1868. doi:10.1016/j.bbmt.2019.05.025
   PubMed Web of Science ®Google Scholar
• Symons HJ, Zahurak M, Cao Y, et al. Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. Blood Adv. 2020;4(16):3913–3925.
   PubMed Web of Science ®Google Scholar
• Dreger P, Sureda A, Ahn KW, et al. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. Blood Adv. 2019;3(3):360–369. doi:10.1182/bloodadvances.2018027748
   PubMed Web of Science ®Google Scholar
• Quarello P, Berger M, Rivetti E, et al. FLAG-liposomal doxorubicin (myocet) regimen for refractory or relapsed acute leukemia pediatric patients. J Pediatr Hematol Oncol. 2012;34(3):208–216. doi:10.1097/MPH.0b013e3182427593
   PubMed Web of Science ®Google Scholar
• Fong CY, Grigoriadis G, Hocking J, et al. Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse. Leuk Lymphoma. 2013;54(2):336–341. doi:10.3109/10428194.2012.713479
   PubMed Web of Science ®Google Scholar
• Yilmaz BS, Ataseven E, Kizmazoglu D, et al. Nüks/refrakter akut lösemili Çocuklarda İdarubisin eklenerek veya eklenmeden FLAG tedavisi: Bir türk pediatrik hematoloji merkezi deneyimi. Turkish J Hematol. 2017;34(1):46–51. doi:10.4274/Tjh.2015.0411
   PubMedGoogle Scholar
• Shargian-Alon L, Wolach O, Rozovski U, et al. Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia. Ann Hematol 2020;99(12):2939–2945. doi:10.1007/s00277-020-04232-x
   PubMed Web of Science ®Google Scholar
• Wang L, Devillier R, Wan M, et al. Clinical outcome of FLAG-IDA chemotherapy sequential with Flu-Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes. Bone Marrow Transplant. 2019;54(3):458–464. doi:10.1038/s41409-018-0283-5
   PubMed Web of Science ®Google Scholar
• Law AD, Salas MQ, Lam W, et al. Reduced intensity conditioning and dual T-lymphocyte suppression with anti-thymocyte globulin and post-transplant cyclophosphamide as graft versus host disease prophylaxis In haploidentical stem cell transplants For hematological malignancies. biology of blood & marrow transplantation. J Am Soc Blood Marrow Transpl. 2018;24(11):2259–2264.
   PubMed Web of Science ®Google Scholar
• Mccurdy SR, Kanakry JA, Showel MM, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015;125(19):3024–3031. doi:10.1182/blood-2015-01-623991
   PubMed Web of Science ®Google Scholar
• Klein OR, Buddenbaum J, Tucker N, et al. Nonmyeloablative haploidentical bone marrow transplantation with post-transplantation cyclophosphamide for pediatric and young adult patients with high-risk hematologic malignancies. Biol Blood Marrow Transpl. 2017;23(2):325–332. doi:10.1016/j.bbmt.2016.11.016
   PubMed Web of Science ®Google Scholar
• Maher OM, Silva JG, Wu J, et al. Outcomes of children, adolescents, and young adults following allogeneic stem cell transplantation for secondary acute myeloid leukemia and myelodysplastic syndromes-The MD Anderson Cancer Center experience. Pediatr Transplant. 2017;21(3):e12890–e12898. doi:10.1111/petr.12890
   Web of Science ®Google Scholar
• Molina B, Gonzalez VM, Herrero B, et al. Kinetics and risk factors of relapse after allogeneic stem cell transplantation in children with leukemia: A long-term follow-Up single-center study. Biol Blood Marrow Transplant. 2018;25(1):100–106.
   PubMed Web of Science ®Google Scholar
• Farooq MU, Mushtaq F, Farooq A, et al. FLAG vs FLAG-IDA: outcomes in relapsed/refractory acute leukemia. Cancer Chemot Pharm. 2019;83(6):1191–1193.
   PubMed Web of Science ®Google Scholar
• Westhus J, Noppeney R, Schmitz C, et al. Etoposide combined with FLAG salvage therapy is effective in multiple relapsed/refractory acute myeloid leukemia. Acta Haematol 2019;143(5):1–8.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Othus M, Araki D, et al. Pre- and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia. 2016;30(7):1456–1464. doi:10.1038/leu.2016.46
   PubMed Web of Science ®Google Scholar